Cargando…
A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...
Autores principales: | Watanabe, Marika, Yakushijin, Kimikazu, Funakoshi, Yohei, Ohji, Goh, Ichikawa, Hiroya, Sakai, Hironori, Hojo, Wataru, Saeki, Miki, Hirakawa, Yuri, Matsumoto, Sakuya, Sakai, Rina, Nagao, Shigeki, Kitao, Akihito, Miyata, Yoshiharu, Koyama, Taiji, Saito, Yasuyuki, Kawamoto, Shinichiro, Yamamoto, Katsuya, Ito, Mitsuhiro, Murayama, Tohru, Matsuoka, Hiroshi, Minami, Hironobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695068/ https://www.ncbi.nlm.nih.gov/pubmed/36366338 http://dx.doi.org/10.3390/vaccines10111830 |
Ejemplares similares
-
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
por: Watanabe, Marika, et al.
Publicado: (2022) -
Early diagnosis of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, with modified diagnostic criteria including refractory thrombocytopenia
por: Ichikawa, Hiroya, et al.
Publicado: (2023) -
Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody
por: Funakoshi, Yohei, et al.
Publicado: (2021) -
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
por: Funakoshi, Yohei, et al.
Publicado: (2022) -
Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination
por: Funakoshi, Yohei, et al.
Publicado: (2022)